Second-cycle reviews are now underway for two competing oral testosterone replacement candidates with the recent resubmission of Lipocine Inc.'s Tlando. Clarus Therapeutics Inc. resubmitted its oral testosterone formulation Jatenzo in June.
Lipocine has drawn close to Clarus in the race for the first oral testosterone replacement therapy for men with hypogonadism....








